Pricing Log in Create free account

Cingulate Inc. (CING) vs Champions Oncology, Inc. (CSBR)

Cingulate Inc. and Champions Oncology, Inc. are both Biotechnology companies. Cingulate Inc. and Champions Oncology, Inc. are of similar size ($66.3M and $61.7M). Cingulate Inc. has the higher net margin (0.00% vs −1.87%) and the higher return on invested capital (0.00% vs −626.2%). Across the 13 metrics below, Cingulate Inc. leads on 7 and Champions Oncology, Inc. on 6.

Valuation

Metric CING CSBR Biotechnology median
P/E n/m n/m 10.60
P/S n/m 1.10 9.40
P/B 2.39 14.96 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 200.80 0.66
EV/Sales n/m 1.03 9.02
Earnings yield (86.36%) (1.67%) (32.88%)
Free cash flow yield (37.28%) (9.16%) (23.13%)

Profitability

Metric CING CSBR Biotechnology median
Gross margin 0.00% 49.82% 68.51%
Operating margin 0.00% (1.68%) 0.00%
Net margin 0.00% (1.87%) 0.00%
Free cash flow margin 0.00% (10.08%) 0.00%
Return on equity (198.74%) (28.38%) (51.96%)
Return on assets (123.76%) (3.56%) (46.06%)
Return on invested capital 0.00% (626.23%) 0.00%

Growth

Metric CING CSBR Biotechnology median
Revenue growth (TTM) — 6.65% 6.76%
EPS growth (last fiscal year) 59.12% (124.24%) 29.88%
Revenue growth, 5-year CAGR — 7.68% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CING CSBR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.50 1.03 4.97
Net debt to EBITDA 0.51 (20.56) 1.01

Dividend

Metric CING CSBR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CING CSBR Biotechnology median
Market cap 61.66m 66.26m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack